AbbVie Inc said on Friday it has halted enrollment of patients in all ongoing studies testing its brain cancer treatment after the drug failed to meet the main goal in a late-stage trial.
AbbVie halts enrollment after brain cancer trial misses goal, shares fall
More from Pharma NewsMore posts in Pharma News »
- Brazil coronavirus deaths climb to 46,510, cases near 1 million
- Requiring masks ‘political hazard’ as COVID-19 surges in California breadbasket
- Mothers as ‘trauma surgeons:’ the anguish of raising black boys in America
- Record spike in new coronavirus cases reported in six U.S. states as reopening accelerates